Advertisement
Advertisement

BIOA

BIOA logo

BioAge Labs, Inc. Common Stock

16.27
USD
Sponsored
-0.14
-0.87%
Mar 26, 15:59 UTC -4
Closed
exchange

After-Market

16.27

0.00
+0.02%

BIOA Earnings Reports

Positive Surprise Ratio

BIOA beat 3 of 5 last estimates.

60%

Next Report

Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$918.00K
/
-$0.67
Implied change from Q4 25 (Revenue/ EPS)
--
/
--
Implied change from Q1 25 (Revenue/ EPS)
-36.73%
/
+86.11%

BioAge Labs, Inc. Common Stock earnings per share and revenue

On Mar 19, 2026, BIOA reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.75 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 1.43 million, with a --% difference.
Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.67 USD, with revenue projected to reach 918.00 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
logo
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
logo
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
logo
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
logo
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
logo
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
logo
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
logo
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
logo
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-
Actual
-$0.71
Surprise
-
logo
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
For Q4 2025, BioAge Labs, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
The next earning report is scheduled for May 04, 2026.
Based on 5 analysts, BioAge Labs, Inc. Common Stock is expected to report EPS of -$0.67 and revenue of $918.00K for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement